AstraZeneca PLC (AZN)vsZimmer Biomet Holdings Inc (ZBH)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
ZBH
Zimmer Biomet Holdings Inc
$87.33
+0.74%
HEALTHCARE · Cap: $17.13B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 619% more annual revenue ($60.44B vs $8.41B). AZN leads profitability with a 17.2% profit margin vs 9.1%. ZBH appears more attractively valued with a PEG of 0.63. ZBH earns a higher WallStSmart Score of 69/100 (B-).
AZN
Buy64
out of 100
Grade: C+
ZBH
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+20.4%
Fair Value
$120.04
Current Price
$87.33
$32.71 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Earnings expanding 34.1% YoY
Areas to Watch
Moderate valuation
Distress zone — elevated risk
ROE of 5.2% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ZBH
The strongest argument for ZBH centers on Price/Book, PEG Ratio, EPS Growth. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : ZBH
The primary concerns for ZBH are Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while ZBH is a value play — different risk/reward profiles.
ZBH carries more volatility with a beta of 0.47 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
ZBH scores higher overall (69/100 vs 64/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Zimmer Biomet Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?